Answers are grounded in this paper and cite their sources.
Cohort study finds GLP-1 receptor agonists reduce hepatic decompensation risk in underrepresented populations, suggesting efficacy in diversity.
In this diverse nationwide cohort, initiation of GLP-1RAs was associated with a significantly reduced risk of hepatic decompensation compared with DPP4is. These findings extend prior evidence by demonstrating this association in a cohort enriched for populations historically underrepresented in biomedical research.
No takes yet. Share an insight, caveat, or question.
Hwang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: